Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

Background Ipilimumab is an antibody that targets the cytotoxic T-lymphocyte antigen-4 to potentiate an antitumor response. Adding ipilimumab 10 mg/kg to paclitaxel (PTX) and carboplatin (CBDCA) in a phased schedule improved progression-free survival in a phase II non-small-cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Horinouchi, Hidehito, Yamamoto, Noboru, Fujiwara, Yutaka, Sekine, Ikuo, Nokihara, Hiroshi, Kubota, Kaoru, Kanda, Shintaro, Yagishita, Shigehiro, Wakui, Hiroshi, Kitazono, Satoru, Mizugaki, Hidenori, Tokudome, Takuto, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491360/
https://www.ncbi.nlm.nih.gov/pubmed/25924991
http://dx.doi.org/10.1007/s10637-015-0243-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491360/
https://www.ncbi.nlm.nih.gov/pubmed/25924991
http://dx.doi.org/10.1007/s10637-015-0243-5

Ejemplares similares